tau imaging news means memory clinics can now add an FDA-approved tau PET scan to Alzheimer's evaluations for adults with cognitive impairment. Tau means tangled tau protein inside brain cells, and the scan shows whether that tangle pattern is present. This does not replace the standard workup. Clinics still pair history, thinking tests, and amyloid checks with imaging to reach a diagnosis and guide treatment choices.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What does the new scan add to an evaluation?
- How well does the new scan perform?
- What are the limits of a tau PET result?
- Where do blood tests fit before a scan?
What does the new scan add to an evaluation?
On Aug. 14, 2026, FDA approved Tauklarify for brain PET in adults with cognitive impairment being evaluated for Alzheimer's disease, according to NeurologyLive in the FDA approval report. The tracer is florquinitau F18, earlier called MK-6240.
It binds tau tangles so doctors can see tangle pathology during the workup. Updated guidance from the Alzheimer's Association and SNMMI now includes tau PET alongside amyloid PET. The goal is sharper diagnosis in mild impairment and dementia and clearer treatment decisions.
How well does the new scan perform?
Approval rested on two blinded-read studies with five readers, NeurologyLive reported in the same approval coverage. Positive agreement ran 68%-88% and negative agreement 93%-99% against amyloid-PET plus cognition standards. Interreader agreement was strong, with kappa values of 0.92 and 0.86.
A head-to-head study imaged the same person with older Tauvid and newer MK6240, according to Being Patient in the head-to-head imaging summary. MK6240 found tangles earlier and better separated Alzheimer's-related impairment. Discrimination reached AUC 0.93 versus 0.86 for the older tracer.
What are the limits of a tau PET result?
The label limits use to Alzheimer's evaluation. Safety and effectiveness are not established for non-Alzheimer tauopathies, Lantheus stated in its approval notice.
A negative scan does not exclude tau pathology, and a positive scan does not by itself confirm it. That means the scan is one piece of evidence. Your doctor reads it with symptoms, exam results, thinking tests, and amyloid findings before naming a cause.
Where do blood tests fit before a scan?
On Aug. 24, 2026, FDA cleared Roche's Elecsys Phospho-Tau 217P plasma test to aid amyloid assessment in people 55 and older with cognitive signs, according to Roche in the test clearance announcement. P-tau217 is a phosphorylated tau fragment in blood linked to Alzheimer's pathology.
The test can be used in primary and specialty care. Research presented at AAIC 2026 found very high blood p-tau217 in symptom-free older adults carried about 78% risk of impairment over 10 years. A large pooled study found high p-tau217 plus APOE4 predicted symptoms in 3-4 years, versus a longer interval without APOE4. Ask your clinic these practical questions:.
- Do my history and test scores meet criteria for amyloid testing first?
- Would a p-tau217 blood test help decide about PET or spinal fluid testing?
- Would a tau PET result change diagnosis, trial eligibility, or treatment?
- Where is the scan offered, and what preparation and follow-up does it need? Bring a medication list, prior brain scans, and a family member who knows your daily changes.
You Might Also Like
- Tauklarify Imaging for Alzheimer’s Tau Tangles in 2026: A Source-Checked Briefing for Memory Clinic Patients
- PrecivityAD2 as an Adjunct to a 2026 Alzheimer’s Assessment: A Source-Checked Briefing for Memory Clinic Patients
- PrecivityAD2 and Younger-Onset Alzheimer’s Diagnosis in 2026: A Source-Checked Briefing for Memory Clinic Patients
